SECOND AMENDMENT TO MASTER CLINICAL STUDY AGREEMENT
Between
WYETH PHARMACEUTICALS INC.
and
THE UNIVERSITY OF TEXAS SYSTEM

This Second Amendment to the Master Clinical Study Agreement ("Amendment") dated June 16, 2009, and made effective as of July 22, 2009 ("Effective Date"), is made among Wyeth Pharmaceuticals Inc., acting through its division, Wyeth Research (hereinafter referred to as "Company") and each of The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas (each an "Institution" and, collectively, the "Institutions"), and each a member institution of The University of Texas System, as governed by its Board of Regents.

WHEREAS, Company and Institutions wish to amend the Master Clinical Study Agreement (the "Agreement") to extend the termination date of the Agreement for an additional 12 months.

NOW, THEREFORE, Company and Institutions for valuable consideration and intending to be legally bound, agree as follows:

1. The first sentence of Section 13.1 (Termination of Master Agreement) of the Agreement is hereby deleted in its entirety and shall be replaced with the following:

   "The term of this Master Agreement shall begin upon the Effective Date and shall continue for the longer of seven (7) years from the Effective Date or until the obligations under all Protocol Agreements are fully performed, unless sooner terminated in accordance with this Article 13."

2. All other terms of the Agreement, as amended, shall remain the same and in full force and effect.

3. This Amendment may be executed in one or more counterparts and the counterparts, together, shall constitute a single agreement.

   (signature page follows)
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: [Signature]
Duly authorized
Joseph S. Camardo, MD
Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center at San Antonio

By: [Signature]
Name: Jane A. Youngren
Title: Assistant Vice President for Research
Date: 7-1-09

The University of Texas M. D. Anderson Cancer Center

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Southwestern Medical Center at Dallas

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Medical Branch at Galveston

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Health Science Center at Tyler

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: [Signature]
Duly authorized
Joseph S. Camardo, MD
Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center at San Antonio
By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Health Science Center at Houston
By: [Signature]
Name: Jodi S. Ogden
Title: Contracts Director
Office of Sponsored Projects
Date: 6/17/09

The University of Texas M. D. Anderson Cancer Center
By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Southwestern Medical Center at Dallas
By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Medical Branch at Galveston
By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

The University of Texas Health Science Center at Tyler
By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: ________________________________
Duly authorized
Joseph S. Camardo, MD
Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center
at San Antonio

By: ________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________

The University of Texas M. D. Anderson Cancer
Center

By: ________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________

The University of Texas Southwestern Medical
Center at Dallas

By: ________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________

The University of Texas Health Science Center
at Houston

By: ________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________

The University of Texas Medical Branch at
Galveston

By: ________________________________
Name: Susan E. Ramsey
Title: Manager of Research Operations
Date: June 16, 2009

The University of Texas Health Science Center
at Tyler

By: ________________________________
Name: ________________________________
Title: ________________________________
Date: ________________________________
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: ________________________________
   Duly authorized
   Joseph S. Camardo, MD
   Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center
at San Antonio

By: ________________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________

The University of Texas M. D. Anderson Cancer Center

By: ________________________________
Name: Melinda Cotten, CRA
Title: Executive Director, Sponsored Programs
Date: 6/25/09

The University of Texas Southwestern Medical Center at Dallas

By: ________________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________

The University of Texas Medical Branch at Galveston

By: ________________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________

The University of Texas Health Science Center at Tyler

By: ________________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________

Reviewed and Approved by
UTMDACC Legal Services for
UTMDACC Signature:

[Signature]
6.25.2009
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: ____________________________
Duly authorized
Joseph S. Camardo, MD
Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center at San Antonio

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas M. D. Anderson Cancer Center

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Health Science Center at Houston

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Southwestern Medical Center at Dallas

By: ____________________________
Name: Perrie M. Adams, Ph.D.
Title: Associate Dean for Research
Date: 6/14/09

The University of Texas Medical Branch at Galveston

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Health Science Center at Tyler

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________
IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by an authorized representative and effective as of the Effective Date set forth above.

ACCEPTED AND AGREED TO:

WYETH PHARMACEUTICALS INC.,
acting through its division, Wyeth Research

By: ____________________________
    Duly authorized
    Joseph S. Camardo, MD
    Senior Vice President, Global Medical Affairs

The University of Texas Health Science Center
at San Antonio

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas M. D. Anderson Cancer Center

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Health Science Center
at Houston

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Southwestern Medical Center at Dallas

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

The University of Texas Medical Branch at
Galveston

By: ____________________________
Name: __________________________
Title: __________________________
Date: __________________________

By: ____________________________
Name: __ Conna Sutton
Title: Director, Pre-Award Services
Date: 6/25/09